Abstract:Background: Lipoarabinomannan (LAM) is a major antigen of Mycobacterium tuberculosis (MTB). In this report, we evaluated the ability of a novel immunoassay to measure concentrations of LAM in sputum as a biomarker of bacterial load prior to and during treatment in pulmonary tuberculosis (TB) patients. Methods and findings: Phage display technology was used to isolate monoclonal antibodies binding to epitopes unique in LAM from MTB and slow-growing nontuberculous mycobacteria (NTM). Using these antibodies, a sandwich enzyme-linked immunosorbent assay (LAM-ELISA) was developed to quantitate LAM concentration. The LAM-ELISA had a lower limit of quantification of 15 pg/mL LAM, corresponding to 121 colony-forming units (CFUs)/mL of MTB strain H37Rv. It detected slow-growing NTMs but without cross-reacting to common oral bacteria. Two clinical studies were performed between the years 2013 and 2016 in Manila, Philippines, in patients without known human immunodeficiency virus (HIV) coinfection. In a case-control cohort diagnostic study, sputum specimens were collected from 308 patients (aged 17-69 years; 62% male) diagnosed as having pulmonary TB diseases or non-TB diseases, but who could expectorate sputum, and were then evaluated by smear microscopy, BACTEC MGIT 960 Mycobacterial Detection System (MGIT) and Lowenstein-Jensen (LJ) culture, and LAM-ELISA. Some sputum specimens were also examined by Xpert MTB/RIF. The LAM-ELISA detected all smear- and MTB-culture-positive samples (n = 70) and 50% (n = 29) of smear-negative but culture-positive samples (n = 58) (versus 79.3%; 46 positive cases by the Xpert MTB/RIF), but none from non-TB patients (n = 56). Among both LAM and MGIT MTB-culture-positive samples, log10-transformed LAM concentration and MGIT time to detection (TTD) showed a good inverse relationship (r = -0.803, p < 0.0001). In a prospective longitudinal cohort study, 40 drug-susceptible pulmonary TB patients (aged 18-69 years; 60% male) were enrolled during the first 56 days of the standard 4-drug therapy. Declines in sputum LAM concentrations correlated with increases of MGIT TTD in individual patients. There was a 1.29 log10 decrease of sputum LAM concentration, corresponding to an increase of 221 hours for MGIT TTD during the first 14 days of treatment, a treatment duration often used in early bactericidal activity (EBA) trials. Major limitations of this study include a relatively small number of patients, treatment duration up to only 56 days, lack of quantitative sputum culture CFU count data, and no examination of the correlation of sputum LAM to clinical cure. Conclusions: These results indicate that the LAM-ELISA can determine LAM concentration in sputum, and sputum LAM measured by the assay may be used as a biomarker of bacterial load prior to and during TB treatment. Additional studies are needed to examine the predictive value of this novel biomarker on treatment outcomes.

Evaluation of lipoarabinomannan-38kD-IgG test in clinical diagnosis of tuberculosis

The Diagnostic Efficiency Evaluation of Combination Tuberculosis Interferon-Gamma Release Assay with Human Leukocyte Antigen-G for Tuberculosis

Diagnostic value of Lipoarabinomannan antigen for detecting Mycobacterium tuberculosis in adults and children with or without HIV infection

Lipoarabinomannan in sputum to detect bacterial load and treatment response in patients with pulmonary tuberculosis: Analytic validation and evaluation in two cohorts

Real-world diagnostic accuracy of lipoarabinomannan in three non-sputum biospecimens for pulmonary tuberculosis disease

Novel automated AIMLAM for diagnosis of Mycobacterium tuberculosis

Utility of Urine Lipoarabinomannan (LAM) in Diagnosing Mycobacteria Infection among Hospitalized HIV-positive Patients

An improved algorithm for rapid diagnosis of pleural tuberculosis from pleural effusion by combined testing with GeneXpert MTB/RIF and an anti-LAM antibody-based assay

Diagnostic accuracy of Lipoarabinomannan detection by lateral flow assay in pleural tuberculosis

Performance of urine lipoarabinomannan assays for paediatric tuberculosis in Tanzania

Urinary lipoarabinomannan in individuals with sputum-negative pulmonary tuberculosis

Diagnostic value of the cerebrospinal fluid lipoarabinomannan assay for tuberculous meningitis: a systematic review and meta-analysis

Exploring the eligibility of all reported lipoarabinomannan-testing assays in different clinical situations: a systematic review and meta-analysis of 97 articles

Development and evaluation of a novel multiple-antigen ELISA for serodiagnosis of tuberculosis.

Determination of Lipoprotein Z-Specific IgA in Tuberculosis and Latent Tuberculosis Infection

Evaluation of Anti-TBGL Antibody in the Diagnosis of Tuberculosis Patients in China

A Novel Quantitative Urine LAM Antigen Strip for Point-of-care Tuberculosis Diagnosis in Non-Hiv Adults.

The In-Vitro Interferon-Gamma Release Assay for the Diagnosis of Tuberculosis and Mycobacterium Tuberculosis Infections

Application of Mycobacterium Tuberculosis RNA for the Rapid Diagnosis of Lymph Node Tuberculosis Using Different Specimens.

Enzyme-linked Immunospot Assay Combined with Serum Latex Agglutination Test for Diagnosis of Pulmonary Tuberculosis and Concomitant Pulmonary Cryptococcosis

Evaluation of Mycobacterium Tuberculosis-Specific Antibody Responses for the Discrimination of Active and Latent Tuberculosis Infection.